Lixisenatide: Combination Treatment Could Offer Differentiated GLP-1 Advantage to Diabetics
(Thomson Reuters ONE) -
Zealand Pharma (CPH:ZEAL) (OTC: ZLDPF) President and CEO Dr. David Solomon
details timeframes in the development of lixisenatide, a treatment for type-2
diabetes licensed to Sanofi (NYSE:SNY), in an exclusive video interview with
PropThink.com.
"We've had a terrific partnership with [Sanofi] since 2003. They've advanced
this through ten Phase III studies, 38 countries, 400 sites, and over 4300
patients , and we're very pleased to report that the results of all those ten
trials have been positive to date," says Solomon.
Currently lead by Novo Nordisk's (NYSE:NVO) Victoza and Amylin's (NASDAQ:AMLN)
exenatide products, lixisenatide sets itself apart in this growing GLP-1 market
($6B by 2017) with good glycemic control and weight-loss - often difficult for
diabetes patients. They hope to market the treatment as a monotherapy and also
as a combination product with leading global insulin Lantus.
Solomon says Zealand is also seeking partnerships for some of their 11 early-
stage pipeline candidates. He discusses implications of the company's balance
sheet and Zealand's financial outlook for the next few years as they focus on
novel poly-pharmacological approaches to diabetes treatment.
Click here to view our video interview with Zealand Pharma President and CEO Dr.
David Solomon.
About PropThink
PropThink is an intelligence service that delivers long and short trading ideas
to investors in the healthcare and life sciences sectors. Our focus is on
identifying and analyzing technically-complicated companies and equities that
are grossly over or under-valued. We offer daily market coverage, weekly feature
stories, and a newsletter to investors who subscribe on PropThink.com
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: PropThink via Thomson Reuters ONE
[HUG#1625203]
Unternehmensinformation / Kurzprofil:
Datum: 09.07.2012 - 13:26 Uhr
Sprache: Deutsch
News-ID 163293
Anzahl Zeichen: 2444
contact information:
Town:
New York
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 111 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Lixisenatide: Combination Treatment Could Offer Differentiated GLP-1 Advantage to Diabetics"
steht unter der journalistisch-redaktionellen Verantwortung von
PropThink (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
